Chinese automotive price war could affect European markets: Indicata
The ongoing price war in China's electric vehicle (EV) market could impact European new and used car markets, according to Indicata, a unit of Autorola Group.
As Chinese automakers cut prices by up to 34% and EV discounts average 17%, ripple effects could affect car values across Europe and the UK.
The Chinese market is experiencing intense competition with more than 100 EV brands and is projected to exceed 33 million vehicles by 2025.
Indicata global business unit director Andy Shields said: 'Chinese OEMs are facing massive oversupply and intense competition in their domestic market.'
BYD recently announced price cuts across 25 models due to excess inventory, compressing vehicle margins industry-wide.
Indicata's analysis also highlights significant barriers for Chinese manufacturers in other markets.
The US market remains largely inaccessible due to high tariffs.
Other global markets outside Europe could absorb internal combustion engine (ICE) and plug-in hybrid electric vehicles (PHEV) but lack the infrastructure for battery-electric vehicle (BEV) adoption, the technology vendor explained.
Chinese manufacturers are shifting focus from BEVs to ICE and hybrid vehicles.
This strategic shift addresses tariff considerations and slower-than-expected BEV demand.
Indicata projects increasing pressure on the EU, UK, Brazil, Mexico, and Australia to absorb Chinese vehicles, including PHEVs.
'Whilst there are tariffs in place for BEVs in the EU, it's still possible for Chinese manufacturers to sell BEVs in Europe more profitably than in their home market,' Shields added.
'The UK market is particularly exposed, as there are currently no additional tariffs on Chinese BEVs.
Indicata said that the competitive landscape is unsustainable, with most manufacturers needing one million vehicle production annually for profitability.
Only a few brands, including BYD, Li Auto, and Seres, report consistent margins while others such as Nio face cash burn impacting profits.
Industry consolidation appears unavoidable as smaller firms confront acquisition or risk exiting the market, Indicata said.
Recognising the sector's instability, the Chinese Government is signalling broader shifts ahead for the global automotive landscape.
Chinese EV manufacturers aim for 50% of sales from international markets, with exports already at 33% of China's total EV production in early 2025.
However, this strategy risks geopolitical tensions, evolving tariffs, and regulatory barriers.
European consumers may benefit from lower-priced, advanced vehicles in the short term, but long-term implications for used car markets could be significant, as competitively priced Chinese vehicles might pressure used vehicle valuations.
Automakers such as Volkswagen and Honda struggle to compete with Chinese EVs, while the price war in China further challenges Western manufacturers.
These OEMs may focus more on their home markets in Europe, leading to increased competition and price wars to avoid CO₂ penalties, impacting sales of both new and used vehicles during 2025.
"Chinese automotive price war could affect European markets: Indicata" was originally created and published by Motor Finance Online, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
FAW Toyota launches new bZ5 electric SUV
FAW Toyota Motor Company, one of Toyota's main Chinese joint ventures, officially launched its new competitively-priced bZ5 battery-powered SUV on the local market, as the Japanese automaker looks to strengthen its foothold in China's fast-expanding new energy vehicle (NEV) market. The new bZ5 is available initially in four main variants, the 550 Joy, 550 Pro, 550 Pro Smart Drive and the 630 Pro, offering varying levels of equipment and trim, and with prices ranging between CNY 129,800 and CNY 159,800 yuan (US$ 18,100-US$ 22,300), inclusive of manufacturer incentives. The bZ5 550 models are powered by 200 kW motors, with their standard battery pack offering a maximum range of 550 km on a single charge. The come with features such as 16-inch central touchscreen, 5G connectivity, and AI-powered voice control. The 630 Pro model has an extended range of 630 km. The bZ5 range is designed to compete with the Tesla Model Y, China's best-selling battery-powered SUV, and is priced significantly lower than the Model Y's starting price of CNY263,500 while offering a similar range. "FAW Toyota launches new bZ5 electric SUV" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
20 minutes ago
- Yahoo
BYD Introduces Most Affordable EV Model in the United Kingdom
BYD Company Limited BYDDY, an EV manufacturer in China, has introduced its most affordable model in the United Kingdom as part of its broader strategy to surpass Tesla as the world's leading electric vehicle manufacturer. The newly launched Dolphin Surf is the European version of BYD's top-selling Chinese model, the Seagull, which recently saw its price drop to just $7,800 in China following further the China Automobile Manufacturers Association didn't name BYD directly, it recently cautioned that ongoing price reductions are fueling fears of a renewed price war in the Chinese EV market. BYD's Dolphin Surf, priced from around $25,000, appears to be extending that pricing pressure into the United Kingdom, BYD outpaced Tesla in monthly vehicle registrations last month, selling 3,025 vehicles compared to Tesla's 2,016 units, and is on track to challenge Tesla's full-year performance. In April, BYD also overtook Tesla in European registrations for the first time, even before the Dolphin Surf entered the the UK's least expensive EV is the Dacia Spring, starting at $20,000 with a WLTP range of 140 miles. BYD's base Dolphin Surf 'Active' variant offers a 203-mile range, while the 'Boost' version extends that to 305 miles and starts at $30,000. Both models come equipped with premium features, such as a 10.1-inch rotatable touchscreen and smart driving functions. Although EVs already tend to be cheaper to own than petrol cars, the emergence of compact, low-cost EVs is seen as key to attracting more budget-conscious buyers. BYD's rapid growth in Europe continues despite the European Union imposing 17.4% tariffs on its vehicles due to concerns over Chinese government subsidies. The United Kingdom, however, has not imposed such tariffs, making it an attractive and increasingly important market for BYD. BYD has a Zacks Rank #5 (Strong Sell) at better-ranked stocks in the auto space are CarGurus, Inc. CARG, Strattec Security Corporation STRT and Michelin MGDDY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks Zacks Consensus Estimate for CARG's 2025 sales and earnings implies year-over-year growth of 4.96% and 25%, respectively. EPS estimates for 2025 and 2026 have improved 30 cents and 44 cents, respectively, in the past 60 Zacks Consensus Estimate for STRT's fiscal 2025 sales and earnings implies year-over-year growth of 3.49% and 8.11%, respectively. EPS estimates for fiscal 2025 and 2026 have improved 73 cents and 91 cents, respectively, in the past 60 Zacks Consensus Estimate for MGDDY's 2025 sales and earnings implies year-over-year growth of 1.69% and 37.76%, respectively. EPS estimates for 2025 have improved a penny in the past 30 days. EPS estimates for 2025 have improved 3 cents in the past seven days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Strattec Security Corporation (STRT) : Free Stock Analysis Report Michelin (MGDDY) : Free Stock Analysis Report CarGurus, Inc. (CARG) : Free Stock Analysis Report Byd Co., Ltd. (BYDDY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data